Wide Ranks

LEGN

Legend Biotech Corporation

43.13

Top Statistics
Market Cap 7 B Forward PE -79.70 Revenue Growth 66.90 %
Current Ratio 4.98 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -66.92 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -43.92 Enterprise / Revenue 28.76 Price To Sales Trailing12 Months 15.21
Profitability
Profit Margins -66.92 % Operating Margins -43.92 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 3.30 Total Debt 346 M
Total Debt To Equity 31.05 Current Ratio 4.98 Book Value Per Share 6.08
All Measures
Short Ratio 1280.00 % Message Board Id finmb_552805228 Shares Short Prior Month 11 M
Return On Equity -0.2835 City Somerset Uuid ccaf9204-94bb-3c10-bdb1-a5d800652e71
Previous Close 42.58 First Trade Date Epoch Utc 1 B Book Value 6.08
Beta 0.1140 Total Debt 346 M Volume 1 M
Price To Book 7.09 Fifty Two Week Low 36.92 Total Cash Per Share 3.30
Total Revenue 520 M Shares Short Previous Month Date 1 B Target Median Price 84.50
Max Age 86400 Recommendation Mean 1.64 Sand P52 Week Change 0.3133
Operating Margins -43.92 % Target Mean Price 82.55 Net Income To Common -348128000
Short Percent Of Float 0.2385 Implied Shares Outstanding 182 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 1 B Next Fiscal Year End 1 B Revenue Per Share 2.85
Held Percent Insiders 0.0131 Ebitda Margins -65.47 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 42.58
Target Low Price 60.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 44.44
Open 42.96 Free Cashflow -120406752 State NJ
Dividend Yield 0.00 % Return On Assets -0.1228 Time Zone Short Name EST
Trailing Eps -1.92 Day Low 41.74 Address1 2101 Cottontail Lane
Shares Outstanding 183 M Price Hint 2 Target High Price 95.00
Website https://www.legendbiotech.com 52 Week Change -0.2909 Average Volume 1 M
Forward Eps -0.6700 Recommendation Key buy Quick Ratio 485.90 %
Is_sp_500 False Regular Market Day High 43.56 Profit Margins -66.92 %
Debt To Equity 31.05 Fifty Two Week High 70.13 Day High 43.56
Shares Short 22 M Regular Market Open 42.96 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 28.76 Revenue Growth 66.90 %
Shares Percent Shares Out 0.1249 Operating Cashflow -157600000 Currency USD
Time Zone Full Name America/New_York Market Cap 7 B Is_nasdaq_100 False
Zip 08873 Quote Type EQUITY Industry Biotechnology
Long Name Legend Biotech Corporation Regular Market Day Low 41.74 Held Percent Institutions 0.5121
Current Price 43.13 Enterprise To Ebitda -43.92 Financial Currency USD
Current Ratio 4.98 Gross Margins -16.86 % Industry Disp Biotechnology
Number Of Analyst Opinions 20 Country United States Float Shares 162 M
Two Hundred Day Average 50.46 Enterprise Value 14 B Price To Sales Trailing12 Months 15.21
Forward PE -79.70 Regular Market Volume 1 M Ebitda -340560000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.

Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).

The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.

It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.

The company was founded in 2014 and is based in Somerset, New Jersey.

Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.